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Summary. Gas-liquid chromatographic determina- 
tions of nonesterified and total urinary cholesterol 
were performed in 137 normals, 264 patients with var- 
ious internal diseases without evidence of neoplasias 
or diseases of the kidney or urinary tract, 497 patients 
with malignancies and 236 patients with diseases of 
the kidney, urinary tract infections or prostatic ad- 
enoma with residual urine. A normal range (mean_+ 
2 SD) of 0.2-2.2 mg/24 hours nonesterified cholester- 
ol (NEC) and of 0.3-3,0 rag/24 hours total cholesterol 
(TC) was calculated. 
Values of urinary cholesterol excretion were inde- 
pendent of age and sex and did not correlate with 
cholesterol levels in plasma. Patients with various in- 
ternal diseases, without evidence of neoplasias nor dis- 
eases of the kidney or obstruction of the urinary tract, 
showed normal urinary cholesterol excretions, as did 
patients with infections of the urinary tract. 
However, elevated urinary cholesterol was found 
in patients with diseases of the kidney or urinary 
tract obstruction (prostatic adenoma with residual 
urine), malignant diseases of the urogenital tract 
and metastasing carcinoma of the breast. In patients 
with other malignant diseases urinary cholesterol 
was usually normal. 
Lesions of the urothelial cell membranes are con- 
sidered to be the most likely cause of urinary choles- 
terol hyperexcretion. The clinical value of urinary 
cholesterol determinations a a possible screening test 
for urogenital carcinomas in unselected populations 
is limited by lacking specificity, expensive methodo- 
logy and low prevalence of the mentioned carcinomas, 
although elevated urinary cholesterol excretions have 
been observed in early clinical stages of urogenital 
cancers. 
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Untersuchungen zur klinischen Bedeutung des Freien 
und Gesamtcholesterins im Urin 
Zusammenfassung. Gaschromatographische Bestim- 
mungen yon unverestertem und Gesamtcholesterin im 
Urin wurden bei 137 Normalpersonen, 264 Patienten 
mit verschiedenen internen Erkrankungen, ohne Hin- 
weis far ein Malignom oder eine Erkrankung der 
Nieren und ableitenden Itarnwege, 479 Patienten mit 
Malignomen und 236 Patienten mit Erkrankungen 
der Nie~-e, Infektionen der ableitenden Harnwege oder 
Prostataadenom it Restharn, durchgeffihrt. 
Ein Normalbereich ( ) ( log_+2SD)  yon 0.2- 
2.2 rag/24 Stunden fiir unverestertes Cholesterin und 
yon 0.3,--3.0 mg/24 Stunden ffir Gesamtcholesterin 
wurde errechnet. 
Die Ausscheidung des Cholesterins im Urin war 
unabh~ingig vom Alter und Geschtecht und korrelierte 
nicht mit den Cholesterinwerten im Plasma. Patienten 
mit verschiedenen internen Erkrankungen, ohne Hin- 
weis ffir ein Malignom oder eine Erkrankung der 
Nieren und ableitenden Harnwege, zeigten eine nor- 
male Cholesterinausscheidung im Urin, wie auch Pa- 
tienten mit Harnwegsinfektionen. 
Dagegen wurden ein erh6htes Urincholesterin bei 
Patienten mit Nierenerkrankungen oder Prostata- 
adenomen mit Restharn, malignen Erkrankungen des 
Urogenitaltrakts, owie bei metastasierenden Mam- 
macarcinomen beobachtet. 
Bei Patienten mit Malignomen anderer Lokalisa- 
tion war die Cholesterinausscheidung im Urin ge- 
w6hnlich normal. L~sionen yon Zellmembranen des 
Urothels k6nnen als die wahrscheinlichste Ursache 
einer gesteigerten Cholesterinausscheidung im Urin 
angesehen werden. 
Der klinische Wert der Cholesterinbestimmung im 
Ur inals  m6glicher Screeningtest f ir Urogenitalcar- 
cinome in unselektierten Populationen ist begrenzt 
durch fehlende Spezifit/it, aufwendige Methodik und 
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insbesondere die niedrige Prfivalenz der erwfihnten 
Carcinome, obwohl erh6hte Chotesterinausscheidun- 
gen im Urin auch in Friihstadien yon Urogenitalcar- 
cinomen beobachtet werden konnten. 
Schliisselwiirter: Cholesterin im Urin - diagnostischer 
Wert - Erkrankungen des Urogenitalsystems 
Anisotropic material is a well recognized component 
in the urine sediment of  patients with the nephrotic 
syndrome (Bruger M, 1935; Zimmer JG et al., 1961, 
Klahr Set  al., 1967). It has been pointed out that 
this microscopic material is apparently composed 
largely of cholesterol esters with a smaller proport ion 
of  free cholesterol (Zimmer JG et al., 1961). In addi- 
tion to these findings there were some reports about 
increased urinary cholesterol in kidney diseases with- 
out nephrotic syndrome and various malignant dis- 
eases (Bloch E, Sobotka H, 1938; Sobotka H etal., 
1939; Sobotka H etal., 1940; Trappe W, 1942; 
Bruger M, Ehrlich SB, 1943; Comings DE, 1963). 
Later studies demonstrated a lower incidence, about 
10%, of hypercholesteroluria in cancer (Burchell MM 
et al., 1949; Burchell MM,  Maclagan NF,  1949). Using 
a more specific mass fragmentometric method hyper- 
excretion of urinary cholesterol had been observed in 
single patients with prostatic or bladder carcinomas 
(Frick J, Spiteller G, 1968; Spiteller Get  al., 1971). 
At the same time, a specific gas-liquid chromato- 
graphic method was developed for the determination 
of  nonesterified urinary cholesterol (Vela BA, Aceve- 
do HF, 1969). They determined elevated values of 
this steroid in patients with carcinomas of  steroid 
hormone producing glands and their main target 
tissues (2, 3, 4, 5, 6). It was concluded that determina- 
tions of  urinary cholesterol can be used as an addi- 
tional biochemical test to detect these cancers. 
Part of  these results could be confirmed recently, 
demonstrating considerable diagnostic sensitivity of  
total urinary cholesterol determination in advanced 
prostatic cancer (Chu TM etal., 1975). However, 
as a result of  gross deficiencies in patient selection, 
the clinical value of urinary cholesterol determina- 
tions is still not well defined. 
Own previously published studies demonstrated 
considerable diagnostic sensitivity of nonesterified 
and especially total urinary cholesterol determination 
in prostatic cancer and papil loma or carcinoma of  
the bladder (Jfingst D et al., 1979a, b). Part of these 
results are included in the presented study which was 
carried out in an attempt o evaluate the clinical sig- 
nificance of nonesterified and total cholesterol deter- 
minations in urine with special regard to early stages 
of  urogenital carcinomas. 
In addition, urinary cholesterol measurements 
were performed in patients with nonmalignant dis- 
eases especially of  kidney and urinary tract to investi- 
gate the diagnostic specificity of these parameters. 
Materials and Methods 
The study included a total of 1134 subjects. Normal range for 
nonesterified (NEC) and total urinary cholesterol (TC) was calcu- 
lated using standard procedures and obtained from 137 clinically 
healthy, asyrnptomatic and biochemically normat individuals, 
67 males and 70 females, covering an agerange of 14 to 76 years. 
The 264 patients with various internal diseases consisted of 
75 with endocrine and metabolic, 68 with cardiovascular, 78 with 
gastrointestinal, 27 with respiratory and 16 with haemopoetic dis- 
orders. The presence of neoplasias, kidney diseases and prostatic 
adenoma with residual urine had been excluded in this second 
control group with reasonable certainty. 
A total of 497 patients with a diagnosis of cancer, based on
cytological or histological examinations, were included in the study. 
Only were urinary samples with macroscopically blood contamina- 
tion "discarded, since the presence of occult btood in urine did 
not alter the determination of urinary cholesterol. 
Patients with carcinomas of the prostate, bladder and kidney 
had been classified according to the TNM-system and were divided 
into two groups (T1NoMo-.T2NoM0 and T1NIM0-T4N4Mla). 
Patients with carcinoma f the cervix and corpus uteri wereclassi- 
fied due to the FIGO, patients with breast cancer were divided 
into stage I-II and stage III-IV according to the tCRP. In patients 
with cancer of other origin staging had not been possible in all
cases, therefore, a division in different groups, due to the extension 
of the disease, had not been done. 
236 patients revealed diseases of the kidney, urinary tract infec- 
tions or prostatic adenomas with residual urine which were d ag- 
nosed by standard clinical procedures. 
Glomerular diseases of the kidney were present in 12, tubular 
diseases in 24 and vascular diseases in 11. 29 patients revealed 
an urolithiasis, 15 a renal cyst and 27 a nephrotic syndrome. Renal 
insufficiency of unknown etiology occurred in 29 patients, infec- 
tions of the urinary tract in 32 and prostatic adenoma with residual 
urine in 57. 
Nonesterified and total urinary cholesterol were analyzed in 
2 ml aliquots of 24 h urine with a gas-liquid chromatographic assay 
using 4-androstendione as internal standard and peakheight ratio 
technique for quantitation. This method has been described in 
detail previously (Jiingst et al. 1979a). 
Results 
Normal Subjects 
Based on the statistical analysis of the results, we 
obtained a mean excretion: 0.76 rag/24 h NEC and 
0.92 mg/24 h TC in men and 0.84 mg/24 h NEC and 
0.98 mg/24 h TC in women. The range for normal 
values was calculated as the mean _+ 2 SD including 
95% of the population. On the basis of  these results, 
an upper normal limit: 2.2 mg/24 h NEC and 2.9 mg/ 
24 h TC was determined in men and 2.3 mg/24 h NEC 
and 3.1 mg/24 h TC in women. 
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Fig. 1. Nonesteri f ied and total  ur inary cholesterol  in 
45 patients with carc inoma of the k idney o stage 
T jNoMo-T2NoM0,  • stage T1N1Mo-T4N~Mla  
Control Patients with Various Intetwal Diseases 
In 264 patients with various internal diseases urinary 
excretion of NEC and TC were within the normal 
range, except 3 cases with slightly elevated levels of 
NEC and one patient with elevated TC (NEC range 
0.2-2.4, median 0.7; TC range 0.3-3.1, median 1.0). 
There was not a constant ratio between NEC and 
TC; in most cases nonesterified cholesterol was the 
major component of total urinary cholesterol. No 
correlation between urinary cholesterol excretion and 
cholesterol concentrations in plasma was obtained, 
even in patients with marked hypercholesterolaemia 
urinary cholesterol values were normal. 
Carcinoma of the Prostate 
In prostatic carcinoma (T1NoMo-T2NoMo) hyper- 
excretion of NEC was detected in 9 and of TC in 
11 out of 24 patients (NEC range 0.4-24.2, median 
1.2; TC range 0.5-51.4, median 2.2). In advanced 
clinical stages of the disease (T3NoM0-T~N4Mld) 
elevated levels of NEC were measured in 25 and of 
TC in 27 out of 40 patients (NEC range 0.2-54.3; 
median 4.2; TC range 0.3-98.4, median 10.3). 
Papilloma and Carcinoma of the Bladder 
In papilloma and carcinoma of the bladder 
(T1NoM0-TzNoMo) hyperexcretion of NEC oc- 
curred in 23 and of TC in 29 out of 44 patients (NEC 
range 0.268.4, median 2.7; TC range 0.3-398.4, me- 
dian 7.0). 
In 21 patients with carcinoma of the bladder 
(T3NoMo-T4N4M~a) elevated NEC was detected in 
16 and elevated TC in 19 (NEC range 0.5 29.8, medi- 
an 7.8; TC range 0.6 96.5, median 14.8). 
Carcinoma of the Kidney 
In 20 patients with carcinoma of the kidney 
(T1NoM0-TzNoM0) hyperexcretion of NEC oc- 
curred in 5 and of TC in 11 (NEC range 0.8-,,-15.2, 
median 2.2; TC range 0.9-30.4, median 3.2), In ad- 
vanced clinical stages of the disease (T1N1Mo-  
T4N4Mta) elevated values of NEC were detected in 
11 and of TC in 14 of the 25 patients investigated 
(NEC range 0.7 64.3, median 1.8; TC range 0.7- 
124.4, median 4.4). Single values of these patients 
are illustrated in Fig, 1. 
Carcinoma of the Breast 
From 22 patients with cancer stage I-II, 5 showed 
slightly elevated values of NEC and 3 of TC, which 
could be observed in 21 and 19, respectively, of the 
70 patients with clinical stage III-IV (NEC range 0.6- 
11.8, median 1.8; TC range 0.7-17.8, median 2.2). 
Single values are demonstrated in Fig. 2. 
Carcinoma of the Uterus 
From the 57 patients with carcinoma of the cervix 
19 revealed elevated l vels of NEC and 17 of TC 
(NEC range 0.6-19.6, median 1.8 ; TC range 0.7-35.4, 
median 2.2). 
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Fig. 2. Nonesterified and total urinary cholesterol in 91 patients 
with carcinoma of the breast, o stage I I I ,  • stage III-IV 
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Fig. 3. Nonesterified and total urinary cholesterol in 57 patients 
with carcinoma of the cervix uteri, o stage I-II, • stage II I- IV 
In 40 patients with carcinoma of the corpus uteri 
hyperexcretion f NEC occurred in 13 and of TC 
in 11 (NEC range 0.8-13.2, median 1.9; TC range 
0.9-27.3, median 2.1). The individual results are 
illustrated in Fig. 3 and Fig. 4. 
Carcinoma of the Ovary 
6 out of 19 patients with carcinoma of the ovary re- 
vealed slightly elevated NEC or TC levels (NEC range 
0,4-4.8, median 1.7; TC range 0.6-8.2, median 2.4). 
Carcinoma of the Testes 
In 21 patients with malignant diseases of the testes 
moderate hyperexcretion f NEC was observed in 
5 and of TC in 6 patients (NEC range 0.4-3.8, median 
1.8; TC range 0.5-12.4, median 2.3). 
Other Malignant Diseases 
The 16 patients with carcinoma of the bronchial tract 
showed normal urinary cholesterol values. 4 out of 
28 patients with neoplasms of the gastrointestinal 
tract revealed slightly elevated levels of NEC and 
TC. In the 46 patients with malignant systemic dis- 
eases, hyperexcretion f NEC occurred in 7 and of 
TC in 9 cases (Fig. 5). 
Diseases of the Kidney and Urina~T ract 
In 47 patients with glomerular, tubular or vascular 
diseases of the kidney hyperexcretion f NEC took 
place in 12 and of TC in 20 (NEC range 0.5-6.6, 
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Fig. 4. Nonesterified and total urinary cholesterol in 40 patients 
with carcinoma of the corpus uteri, o stage I-I I ,  • stage II I- IV 
median 1.8; TC range 0.6-11.5, median 2.8) (Fig. 6). 
From the 29 patients with urolithiasis 8 revealed 
elevated levels of NEC and 13 of TC, similar find- 
ings were obtained in 29 patients with renal insuffi- 
ciency of unknown etiology (NEC range 0.3-9.8, 
median 1.5; TC range 0.4-31.5, median 2.6) (Fig. 7). 
In 27 patients with the nephrotic syndrome hyper- 
excretion of NEC was detected in 20 and of TC in 
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cholesterol in 16 patients with carcinoma 
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25 (NEC range 0.8-38.2, median 4.4; TC range 1.0 
93.5, median 12.6). Lower values of excretion were 
measured in 15 patients with renal cysts (NEC range 
0.8-68.4, median 1.7; TC range 1.3-82.4, median 3.5) 
(Fig. 8). 
32 patients with common infections of  the urinary 
tract revealed normal urinary cholesterol excretion 
in all cases. 
Benign Prostatic Hyperplasia with Residual Urine 
The results obtained in the study of patients with 
prostatic hyperplasia and residual urine have been 
published in detail before, hyperexcretion of  NEC 
was observed in 24 and of TC in 37 out of  57 patients 
(NEC range 0.3-49.0, median 2.0; TC range 0.4- 
112.3, median 5.8). 
Discuss ion  
Our results demonstrated pathologic values in pro- 
static carcinoma T1NoMo-T2NoMo in 37% of  NEC 
and 45% of TC. In advanced clinical stages percent- 
age of elevated values increased to 62.5% for NEC 
and 67.5% for TC. 
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These findings are in good agreement with those 
reported recently (Belis and Cenedella 1979). In papil- 
loma of the bladder NEC hyperexcretion was present 
in 56%, elevated levels of TC were determined in 
68%, similar to data obtained in early stages of carci- 
noma of the bladder. In advanced clinical stages hy- 
perexcretion of NEC was observed in 76% and of 
TC in 90%. In early clinical stages of carcinoma of 
the kidney hyperexcretion of NEC was present in 
I 
10o 
Fig. 8. Non•st•r i f led  and  total  u r inary  cholesterol  in 
pat ients with nephrot ic  syndrome • and  renal  
cysts o 
about 25% and of TC in about 55%. Percentage 
of elevated values increased to 44 of NEC and 56 
of TC in further advanced stages. In patients with 
carcinoma of the cervix or corpus uteri elevated levels 
of NEC or TC were detected in approximately 30%, 
comparable to the results of previous tudies (Aceve- 
do et al. 1971; Acevedo et al. 1975). In early clinical 
stages of patients with breast cancer, marked hyperex- 
cretion of urinary cholesterol has not been detected 
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in contrast o patients with metastases. Malignant 
diseases of testes and ovary revealed moderate hyper- 
excretion of urinary cholesterol in 24-31%, in carci- 
nomas of other origin slightly elevated urinary choles- 
terol has been observed in about 12%. 
In view of these results it is concluded that the 
determination f especially total cholesterol in urine 
has a considerable diagnostic sensitivity for carcino- 
mas of the urogenital system. It is more pronounced 
in patients with cancer of the kidney, prostate and 
bladder than uterus, ovary and testis. 
However, urinary cholesterol hyperexcretion 
could not be considered to be a specific sign of uro- 
genital malignancies. Findings also demonstrate ele- 
vated values in patients with prostatic adenoma nd 
residual urine. In addition, hyperexcretion f urinary 
cholesterol is a common finding in kidney diseases, 
irrespective of etiology or any other clinical features. 
However, it is important to note that common infec- 
tions of the urinary tract are not associated with hy- 
perexcretion of urinary cholesterol. 
Discussing the clinical value of the method pre- 
sented one can state that increments ofurinary choles- 
terol are not a specific sign of urogenital malignancies 
but are usually caused by malignant or nonmalignant 
diseases of the urogenital system. 
The application of this method as a possible 
screening test in cancer detection programs eemed 
to be limited only little by lacking specificity or expen- 
sive methodology. In our opinion most important 
is the fact of low prevalence of urogenital carcinomas 
in unselected populations which would lead to low 
predictive values for a positive urinary cholesterol 
test and the presence of urogenital malignancies. 
This does not necessarily exclude the possibility that 
the urinary cholesterol method could be successfully 
applied in preselected populations with increased pre- 
valence of urogenital carcinomas. 
Although the physiologic mechanisms of urinary 
cholesterol excretion are not known, an excretion as 
a protein bound complex was suggested on the basis 
of ultrafiltration studies (Acevedo et al. 1970). 
Enhanced production of lipoproteins by the malig- 
nant cells had been discussed to cause hyperexcretion 
of urinary cholesterol in cancer of steroid hormone 
producing lands or their main target issues (Aceve- 
do et al. 1973). In addition the presence of immun- 
complex nephritis, a well known disease in cancer 
patients, could be responsible partially for elevated 
urinary cholesterol values (Kerkhoven et al. 1973; 
Sutherland and Mardiney 1973; Eagen and Lew- 
is 1977). 
However, in our opinion it is most likely that 
alterations of the urothelial cell membranes with sub- 
sequent loss of lipoproteins are responsible for hyper- 
excretion of urinary cholesterol irrespective of the 
underlying disease. Only in patients with the nephrot- 
ic syndrome seems the positive correlation between 
urinary protein and urinary cholesterol to support 
the suggestions that enhanced filtration of plasma 
lipoproteins, especially the HDL-fraction, is responsi- 
ble for increased lipiduria (Klahr et al. 1967; de Men- 
doza et ai. 1976; Bing and Starup 1935). 
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